Adverum Biotechnologies, Inc. (ADVM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Adverum Biotechnologies, Inc. (ADVM) trades at $4.36 with AI Score 44/100 (Grade C). Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing treatments for ocular diseases. Market cap: $96.26M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for ADVM: ADVM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ADVM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ADVM: the 1 perspectives are evenly split.
How is this calculated? →Adverum Biotechnologies, Inc. (ADVM) Healthcare & Pipeline Overview
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company specializing in ocular and rare diseases, primarily focusing on ADVM-022, a gene therapy candidate targeting chronic retinal conditions like wet age-related macular degeneration. The company operates in a competitive biotechnology landscape, emphasizing single intravitreal injection treatments.
What Is the Investment Thesis for ADVM?
Adverum Biotechnologies, Inc. presents a focused investment opportunity within the gene therapy space, specifically targeting ocular diseases. The primary value driver is ADVM-022, their lead product candidate aimed at treating wet AMD and DME. Successful clinical trial outcomes and subsequent regulatory approval for ADVM-022 would significantly enhance the company's valuation. Key growth catalysts include the progression of ADVM-022 through clinical trials and potential partnerships for commercialization. However, the investment is subject to risks inherent in clinical-stage biotech companies, including clinical trial failures, regulatory hurdles, and competition from existing and emerging therapies. The company's market capitalization of approximately $0.10 billion reflects both the potential and the risks associated with its pipeline.
Based on FMP financials and quantitative analysis
ADVM Key Highlights
- Adverum Biotechnologies, Inc. is a clinical-stage company focused on gene therapy for ocular diseases.
- Lead product candidate ADVM-022 targets wet age-related macular degeneration and diabetic macular edema.
- The company has strategic collaborations with University of California, Cornell University, GenSight, Lexeo, and Virovek.
- Adverum's approach involves a single intravitreal injection, potentially reducing treatment burden.
- The company operates in the high-growth biotechnology sector, specifically within gene therapy.
Who Are ADVM's Competitors?
ADVM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $645.84 | -1.29% | $66.54B | 91 |
| NVS Novartis AG | $155.20 | -2.94% | $296.14B | 57 |
| SNY Sanofi | $42.61 | -1.27% | $102.45B | 58 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ADVM's Key Strengths?
- Focus on gene therapy for ocular diseases.
- Lead product candidate ADVM-022 targets large market.
- Strategic collaborations with universities and biotech companies.
- Single-injection approach offers potential advantages over existing therapies.
What Are ADVM's Weaknesses?
- Clinical-stage company with no approved products.
- Reliance on ADVM-022 for near-term value creation.
- Limited financial resources compared to larger pharmaceutical companies.
- Susceptible to clinical trial failures and regulatory setbacks.
What Could Drive ADVM Stock Higher?
- Announcement of clinical trial results for ADVM-022 in wet AMD and DME.
- Potential regulatory submissions for ADVM-022 to the FDA and other agencies.
- Progression of ADVM-022 through clinical development milestones.
- Potential strategic partnerships with larger pharmaceutical companies.
What Are the Key Risks for ADVM?
- Financial-distress signal — its Altman Z-Score of -32.54 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $7.2M recently.
- Clinical trial failures or delays for ADVM-022.
- Regulatory setbacks or rejection of ADVM-022.
- Competition from existing and emerging therapies for wet AMD and DME.
- Adverse events associated with gene therapy.
- Dependence on the success of ADVM-022.
What Are the Growth Opportunities for ADVM?
- Growth opportunity 1: Successful clinical development and commercialization of ADVM-022 for wet AMD represents a significant growth opportunity. The global wet AMD market is projected to reach billions of dollars, driven by an aging population and increasing prevalence of the disease. Adverum's single-injection gene therapy could capture a substantial share of this market by offering a more convenient and potentially more effective treatment option compared to current therapies requiring frequent injections. Timeline for commercialization depends on successful clinical trial outcomes and regulatory approvals, potentially within the next 3-5 years.
- Growth opportunity 2: Expanding the application of ADVM-022 to treat diabetic macular edema (DME) provides another substantial growth avenue. The DME market is also experiencing growth, driven by the increasing prevalence of diabetes globally. If ADVM-022 proves effective in treating DME, it could significantly expand Adverum's addressable market. Clinical trials for DME are ongoing, and positive results could lead to regulatory submissions and potential commercialization within a similar timeframe as wet AMD.
- Growth opportunity 3: Strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of Adverum's gene therapy pipeline. Collaborations could provide access to additional funding, expertise, and distribution networks, enhancing Adverum's ability to bring its products to market. Such partnerships could also validate Adverum's technology and increase investor confidence. Discussions with potential partners are likely ongoing, and a deal could materialize within the next 1-2 years.
- Growth opportunity 4: Expanding the pipeline to include gene therapies for other ocular diseases beyond wet AMD and DME offers long-term growth potential. Adverum could leverage its expertise in gene therapy and ophthalmology to develop treatments for conditions such as glaucoma, retinitis pigmentosa, and other inherited retinal diseases. This would diversify the company's product portfolio and reduce its reliance on ADVM-022. Research and development efforts in this area are ongoing, with potential for new clinical candidates to emerge in the next 3-5 years.
- Growth opportunity 5: Exploring gene therapy applications for rare diseases beyond ophthalmology represents a longer-term growth opportunity. Adverum's gene therapy platform could potentially be adapted to treat rare genetic disorders affecting other organ systems. This would require significant investment in research and development, but could open up new markets and revenue streams. This is a longer-term strategy, with potential for clinical programs to begin in 5+ years.
What Opportunities Does ADVM Have?
- Successful clinical development and commercialization of ADVM-022.
- Expansion of ADVM-022 to treat other ocular diseases.
- Strategic partnerships with larger pharmaceutical companies.
- Development of gene therapies for rare diseases.
What Threats Does ADVM Face?
- Competition from existing and emerging therapies for wet AMD and DME.
- Clinical trial failures or regulatory delays.
- Adverse events associated with gene therapy.
- Changes in the regulatory landscape for gene therapy products.
What Are ADVM's Competitive Advantages?
- Proprietary gene therapy technology platform.
- Patent protection for ADVM-022 and other product candidates.
- Expertise in developing gene therapies for ocular diseases.
- Strategic collaborations with leading research institutions.
What Does ADVM Do?
Adverum Biotechnologies, Inc., founded in 2006 and headquartered in Redwood City, California, is a clinical-stage gene therapy company dedicated to developing innovative treatments for ocular and rare diseases. Originally named Avalanche Biotechnologies, Inc., the company rebranded in May 2016 to reflect its evolving focus. Adverum's core mission revolves around leveraging gene therapy to address unmet medical needs in ophthalmology. Their lead product candidate, ADVM-022, is a single intravitreal injection gene therapy designed to treat chronic retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). This innovative approach aims to provide long-term therapeutic benefits with a single administration, reducing the burden of frequent injections for patients. Adverum has established strategic license and collaboration agreements with leading research institutions such as the University of California and Cornell University, as well as biotech companies like GenSight, Lexeo, and Virovek, to enhance its research and development capabilities. The company's focus on gene therapy positions it within a rapidly advancing field, with the potential to transform the treatment landscape for debilitating eye conditions.
What Products and Services Does ADVM Offer?
- Develop gene therapy product candidates for ocular diseases.
- Focus on single intravitreal injection treatments.
- Target chronic retinal diseases like wet age-related macular degeneration (wet AMD).
- Target diabetic macular edema (DME).
- Establish license and collaboration agreements with universities and other companies.
- Conduct clinical trials to evaluate the safety and efficacy of their gene therapies.
- Seek regulatory approval for their product candidates from agencies like the FDA.
How Does ADVM Make Money?
- Develop and patent gene therapy technologies.
- Conduct clinical trials to demonstrate efficacy and safety.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Potentially manufacture and sell gene therapy products directly, pending regulatory approval.
What Industry Does ADVM Operate In?
Adverum Biotechnologies, Inc. operates within the biotechnology industry, which is characterized by rapid innovation and high-risk, high-reward ventures. The gene therapy segment is experiencing significant growth, driven by advancements in vector technology and a better understanding of disease mechanisms. The competitive landscape includes both established pharmaceutical companies and emerging biotech firms, all vying for market share in lucrative therapeutic areas like ophthalmology. Adverum's focus on single-injection gene therapies for retinal diseases positions it to potentially disrupt the existing treatment paradigm, which often involves frequent intravitreal injections. The market for wet AMD and DME treatments is substantial, with a growing aging population driving demand.
Who Are ADVM's Key Customers?
- Patients with wet age-related macular degeneration (wet AMD).
- Patients with diabetic macular edema (DME).
- Ophthalmologists and retinal specialists who treat these patients.
- Hospitals and clinics that provide eye care services.
Company Profile
Adverum Biotechnologies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Laurent Fischer. ADVM has traded publicly since 2014.
F-Score 1/9Financial Health
Adverum Biotechnologies, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -32.54 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
A current ratio of 0.65 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -199.6%, the inverse of the P/E and a quick read on earnings relative to price.
ADVM Valuation & Market Position
With a $96.26M market cap, Adverum Biotechnologies, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ADVM's quantitative score of 44/100 is below the peer average of 73/100.
FY2026 estForward Outlook
Wall Street analysts project Adverum Biotechnologies, Inc. revenue of about $15.2M for fiscal 2026, with EPS near $-4.83. The estimate reflects 4 contributing analysts.
Net sellingInsider Activity
The most recent 12 insider filings for Adverum Biotechnologies, Inc. break down as 9 sales and 3 purchases. On net that is roughly 771K shares disposed (about $7.2M), a signal worth weighing alongside the fundamentals.
ADVM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ADVM Latest News
No recent news available for ADVM.
ADVM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ADVM.
Price Targets
Wall Street price target analysis for ADVM.
ADVM MoonshotScore
What does this score mean?
The MoonshotScore rates ADVM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Laurent Fischer
Chief Executive Officer
Laurent Fischer serves as the Chief Executive Officer of Adverum Biotechnologies, Inc. His career spans several decades in the pharmaceutical and biotechnology industries. Prior to joining Adverum, he held leadership positions at various companies, bringing extensive experience in drug development, commercialization, and strategic planning. Fischer's background includes a strong focus on ophthalmology and rare diseases, aligning with Adverum's core therapeutic areas. He has a proven track record of driving innovation and growth in the healthcare sector.
Track Record: Under Laurent Fischer's leadership, Adverum Biotechnologies, Inc. has focused on advancing its lead product candidate, ADVM-022, through clinical trials. He has overseen the company's strategic collaborations and partnerships, aiming to accelerate the development and commercialization of its gene therapy pipeline. Key milestones include the progression of ADVM-022 into later-stage clinical trials and efforts to secure funding for ongoing research and development.
Common Questions About ADVM (Healthcare)
What does Adverum Biotechnologies, Inc. do?
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing innovative treatments for ocular diseases, particularly those affecting the retina. Their lead product candidate, ADVM-022, is designed as a single intravitreal injection gene therapy to treat chronic retinal conditions such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's approach aims to provide long-term therapeutic benefits with a single administration, reducing the need for frequent injections, which is a common burden for patients with these conditions. Adverum collaborates with universities and other biotech companies to advance its research and development efforts.
What do analysts say about ADVM stock?
Analyst coverage of Adverum Biotechnologies, Inc. typically focuses on the potential of ADVM-022 and its clinical trial progress. Key valuation metrics include the potential market size for wet AMD and DME treatments, the probability of success for ADVM-022 in clinical trials, and the potential for future partnerships or acquisitions. Analyst consensus generally reflects the high-risk, high-reward nature of clinical-stage biotech companies. Growth considerations include the successful completion of clinical trials, regulatory approvals, and commercialization strategies. Analyst ratings and price targets can vary widely based on individual assessments of these factors.
What are the main risks for ADVM?
The main risks for Adverum Biotechnologies, Inc. are inherent to clinical-stage biotech companies. These include the risk of clinical trial failures or delays, which could significantly impact the company's valuation and future prospects. Regulatory setbacks or rejection of ADVM-022 by agencies like the FDA also pose a significant risk. Competition from existing and emerging therapies for wet AMD and DME could limit the market potential for ADVM-022. Additionally, adverse events associated with gene therapy could negatively impact the company's reputation and clinical development programs. The company's dependence on the success of ADVM-022 also represents a concentration risk.
How does Adverum Biotechnologies, Inc. navigate regulatory approval processes?
Adverum Biotechnologies, Inc. navigates regulatory approval processes by adhering to stringent guidelines set forth by regulatory bodies such as the FDA in the United States. This involves conducting comprehensive preclinical studies to assess the safety and efficacy of ADVM-022, followed by well-designed clinical trials to further evaluate its performance in human subjects. The company maintains detailed documentation of all research and manufacturing processes to ensure compliance with regulatory standards. Adverum also engages in ongoing communication with regulatory agencies to address any questions or concerns and to ensure a smooth and efficient review process. The company's regulatory strategy is crucial for securing approval and bringing its gene therapy products to market.
What are the key growth opportunities for ADVM in healthcare?
Adverum Biotechnologies, Inc. has several key growth opportunities within the healthcare sector, primarily centered around expanding the application of its gene therapy platform. One significant opportunity lies in expanding ADVM-022's use to treat additional ocular diseases beyond wet AMD and DME, such as glaucoma or retinitis pigmentosa. Geographically, Adverum could explore expanding into new markets, particularly in Asia and Europe, where there is a growing demand for advanced therapies for retinal diseases. Furthermore, Adverum could leverage its expertise in gene therapy to develop treatments for rare genetic disorders beyond ophthalmology, diversifying its product portfolio and opening up new revenue streams. These expansion strategies could significantly enhance Adverum's market position and long-term growth prospects.
What are the key factors to evaluate for ADVM?
Adverum Biotechnologies, Inc. (ADVM) holds an AI score of 44/100 (low). Not financial advice.
How frequently does ADVM data refresh on this page?
ADVM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ADVM's recent stock price performance?
Adverum Biotechnologies, Inc. (ADVM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on gene therapy for ocular diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Market projections are estimates and may not be accurate.